Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes
Authors' conclusion
These findings suggest that GLP-1RAs may be beneficial against major adverse cardiorenal events in patients with type 1 diabetes, without compromising safety.
Study context
- Population
- Patients with T1D, national electronic health record data, January 2013 to March 2024
- Participants
- 174,678 patients
- Exposure
- GLP-1RA initiation vs no initiation
- Outcome
- MACE and end-stage kidney disease
- Follow-up
- 5 years
Methodological detailsobservational cohort study, sequential target trial emulation, national electronic health record data, propensity score weighting
- Observational cohort study
- Sequential target trial emulation
- National electronic health record data
- Propensity score weighting
Main finding
As reported in the abstract
MACE · 5-year risk
Each group vs no GLP-1RARisk difference (95% CI)
GLP-1RA
−0.7%(−1.2% to −0.2%)
Each group vs no GLP-1RAHazard ratio (95% CI)
GLP-1RA
0.85(0.77–0.95)
Observational data: associations, not effects.
Further findings
| Outcome | Risk difference (CI) | |
|---|---|---|
| End-stage kidney disease · 5-year riskGLP-1RAvs No GLP-1RAPropensity score weighted | −0.3% (−0.6% to 0%) | |
| −1−0.500.5Difference (linear scale) |
| Outcome | HR (CI) | |
|---|---|---|
| End-stage kidney disease · 5-year riskGLP-1RAvs No GLP-1RAPropensity score weighted | 0.81 (0.69–0.95) | |
| 0.512Hazard ratio (log scale) |
Safety
- No increased risks of hospitalization for DKA or severe hypoglycemia
Original publication
Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes. Nat Med. Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →